IGF2BP1 and ovarian carcinoma: The immune-evasive yet druggable nature of IGF2BP1 in ovarian cancer cells suggests that inhibiting IGF2BP1-RNA interactions with small-molecule inhibitors such as BT or CUB may enhance T cell-mediated tumor cell killing.